Long Term Bio
Long only, biotech, healthcare, short only

Rxi Pharmaceuticals, Significant Upside Of 300% Is Expected In Coming Months

Rxi Pharmaceuticals (NASDAQ:RXII) is an RNAi biotechnology company that is developing RNAi drug candidates for unmet medical needs. One of its main drugs is known as RXI-109 being developed to treat patients with scars. There is a huge unmet medical need for scars, because the FDA/EMA have no approved drugs at all for scarring.

sd-rxRNA Technology

One of the hardships in the past for RNAi pharmaceutical companies, was being able to allow naked siRNA molecules to penetrate into the cells efficiently. Many trials failed with RNAi, because the siRNA molecules were never able to reach their target, because of the degrading of the molecule. Within the last few years though, three RNAi biotechs known as Alnylam (NASDAQ:ALNY...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details